Compare · INM vs MRK
INM vs MRK
Side-by-side comparison of InMed Pharmaceuticals Inc. (INM) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INM and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $375.50B, about 71261.7x INM ($5.3M).
- Over the past year, INM is down 31.5% and MRK is up 79.1% - MRK leads by 110.6 points.
- MRK has hit the wire 16 times in the past 4 weeks while INM has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 1 for INM).
- Company
- InMed Pharmaceuticals Inc.
- Merck & Company Inc.
- Price
- $1.59+0.00%
- $152.19+12.59%
- Market cap
- $5.3M
- $375.50B
- 1M return
- +6.00%
- +20.54%
- 1Y return
- -31.47%
- +79.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 16
- Recent ratings
- 1
- 25
InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest INM
- SEC Form 425 filed by InMed Pharmaceuticals Inc.
- SEC Form 425 filed by InMed Pharmaceuticals Inc.
- InMed Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits
- Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
- SEC Form 425 filed by InMed Pharmaceuticals Inc.
- Large owner Adar1 Capital Management, Llc bought $1,555 worth of shares (1,000 units at $1.55) (SEC Form 4)
- Large owner Vivo Opportunity, Llc bought $31,846 worth of shares (20,546 units at $1.55) (SEC Form 4)
- SEC Form 425 filed by InMed Pharmaceuticals Inc.
- InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Large owner Vivo Opportunity, Llc bought $10,148 worth of shares (6,551 units at $1.55) (SEC Form 4)
Latest MRK
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
- EVP, Access, Policy & Comms Guindo Chirfi sold $1,350,000 worth of shares (10,000 units at $135.00), decreasing direct ownership by 21% to 36,613 units (SEC Form 4)
- EVP, General Counsel Zachary Jennifer exercised 54,927 shares at a strike of $109.78 and sold $10,718,495 worth of shares (80,315 units at $133.46), decreasing direct ownership by 36% to 45,509 units (SEC Form 4)
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $5,942,369 worth of shares (45,320 units at $131.12), decreasing direct ownership by 29% to 110,167 units (SEC Form 4)
- Merck upgraded by Daiwa Securities with a new price target
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $788,773 worth of shares (6,050 units at $130.38), decreasing direct ownership by 4% to 155,487 units (SEC Form 4)
- EVP & Pres. MMD Maraldo David R. exercised 18,706 shares at a strike of $82.25 and sold $2,407,797 worth of shares (18,706 units at $128.72) (SEC Form 4)
- EVP,Chief Info&Digital Officer Williams David Michael exercised 52,847 shares at a strike of $74.49 and sold $6,805,145 worth of shares (52,847 units at $128.77), increasing direct ownership by 0.00% to 31,716 units (SEC Form 4)
- EVP, Access, Policy & Comms Guindo Chirfi sold $1,965,000 worth of shares (15,000 units at $131.00), decreasing direct ownership by 24% to 46,613 units (SEC Form 4)
- SEC Form 10-Q filed by Merck & Company Inc.